Two strategies for prevention of cytomegalovirus infections after liver transplantation

Table 1 Patient demographics n (%)

	All (n = 128)	Prophylaxis (n = 60)	Preemptive therapy (n = 68)	P value
Age (yr)	54 ± 10	52 ± 12	56 ± 8.5	0.04
Sex
Male	90 (70)	42 (70)	48 (71)	1.00
Female	38 (30)	18 (30)	20 (29)
Weight (kg)	80 ± 16	81 ± 13	79 ± 19	0.52
SOFA	9.1 ± 4.0	8.8 ± 3.8	9.4 ± 4.3	0.34
APACHE II	14.2 ± 6.7	13.3 ± 5.5	15.0 ± 7.5	0.13
Lab. MELD at Transplantation	18.5 ± 9.4	18.8 ± 8.8	18.2 ± 9.9	0.73
CMV-status D/R				0.24
-/-	19 (17)	5 (10)	14 (22)
-/+	33 (29)	16 (33)	17 (27)
+/+	60 (54)	28 (57)	32 (51)
+/-	Excluded

Data are expressed as mean ± SD or n (%). Complete CMV-status was unavailable for 16 patients, but was known not to be +/-. D/R: Donor/receptor; CMV: Cytomegalovirus; Lab.MELD: Model of end stage liver disease.

Table 2 Infection/blood count abnormalities n (%)

	All (n = 128)	Prophylaxis (n = 60)	Preemptive therapy (n = 68)	P value
Re - LTx	17 (13)	10 (17)	7 (10)	0.31
Infection	86 (71)	40 (69)	46 (72)	0.84
Sepsis	63 (52)	30 (52)	33 (52)	1.00
Thrombocytopenia (PLT < 50 Gpt/L; > 72 h post-LTx	69 (57)	32 (55)	37 (58)	0.86
Leukocytopenia (WBC < 4 Gpt/L; > 72 h post-LTx)	38 (31)	15 (26)	23 (36)	0.25
Anaemia (Hct < 30%; > 72 h post-LTx)	114 (93)	54 (93)	60 (94)	1.00

GPT: Giga particles; LTx: Liver transplantation; PLT: Platelet count; WBC: White blood cells; Hct: Haematocrit.